Board-of-Directors
CEO & Founder

Fintan Walton

Dr Fintan Walton founded PharmaVentures, a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. 

Over a period of three decades, Fintan has built PharmaVentures into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. Its clients have also included major banks, investment/merchant banks, as well as private equity and venture capital groups. 

Dr Walton majored in Genetics at Trinity College Dublin, Ireland, where he also gained a Ph.D. Prior to his entrepreneurial activities at PharmaVentures, Fintan had built his R&D and commercial experience in biotechnology within management positions at Bass and Celltech plc (1982-1992). 

In 1996, he also founded PharmaDeals, the leading database and publishing business related to deal making data and analytics. Thousands of customers from around the world either bought or subscribed to these PharmaDeals publications. The PharmaDeals business was sold to IMS Health (now IQVIA) in Aug 2012.

Corporate-Advisory
Managing Director

Adrian Dawkes

Adrian is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian led multiple consultancy, licensing and M&A mandates. Notable deals include licensing transactions between MedGenesis and Pfizer, Esteve and Mundipharma, and M&A for a UK diagnostics business with Bruker and the sale of NanoSight to Spectris plc.

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. He has held senior positions with Johnson & Johnson, drug discovery platform company Acumen Bioscience and the Healthcare Consultancy company Execute Technologies. Adrian has over 30 years in the pharmaceutical, biotechnology and in vitro diagnostics sectors.

Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

Corporate-Advisory
Managing Director

Andrew Guise

Andrew is a Managing Director at PharmaVentures and is a member of the Corporate Advisory Team.

Andrew is a highly accomplished executive with a wealth of experience in finance, business development, and leadership. Notable deals including IPOs for IsoTis, Genmab and Thrombogenics, secondaries for Serono ($4bn), divestments of, St Martins Healthcare (hospitals), Degussa Dental, Synthes Stratec (ortho), Plasso to Becton Dickenson (lab supply), Oxxon to Oxford Bio (immunotherapy), Surface Therapeutics to Serentis (dermatology),  Zyentia to Lonza (protein refolding). Andrew has held Board positions at Oxford Biosensors (POC diag), Oxitec (pest control), Prolysis (anti -infectives), Purity Health (reformulation), and Gaia Biotherapeutics (cannabinoids). 

During his professional career Andrew has acted as advisor (SME to FTSE 100), VC investor, and held Board / C suite roles in a number of life science companies across multiple sectors.  Andrew has over 30 years’ experience in all areas of healthcare. Andrew holds a BEng in Biochemical Engineering and a PhD in Protein Refolding.

Corporate-Advisory
Managing Director

Stephen Waterman

Stephen is a Managing Director of PharmaVentures. He joined PharmaVentures in 2012, after a long career in Healthcare Investment Banking. At PharmaVentures, Stephen has originated and worked on a number of strategic advisory, licensing and M&A mandates, assisting his clients find the optimal solutions to their challenges and opportunities.

Prior to joining PharmaVentures, Stephen worked as an equity research analyst at Teather & Greenwood, Commerzbank and Elixir Securities covering a range of domestic and international pharmaceutical and biotechnology companies. Subsequently Stephen moved into Corporate Finance roles within Elixir Securities and Matrix Securities, where he advised a number of public and private diagnostic, therapeutics and medical technology companies on fundraising and M&A.

Before embarking on a career in the City, Stephen was instrumental in establishing Evaluate Pharma as one of the pre-eminent competitive intelligence tools in the healthcare industry. He holds a PhD in Neurology from the University of Cambridge.

Although he has a broad spectrum of experience across many sub-sectors of the Healthcare space, Stephen currently has a focus on Contract Research Organisations, Diagnostic, Medical Technologies and Therapeutics companies.

Executive Assistant
to CEO

Kim du Preez

Kim du Preez joins PharmaVentures as Executive Assistant to the CEO. Kim began her career as EA to the head of Equity Capital Markets at Deutsche Bank and from there has gained vast experience across various industries such as IT, consultancy, Education and Logistics working for Senior level executives. Kim holds qualifications in Marketing and Information Technology from the University of South Africa.

Corporate-Advisory
Snr. Marketing Manager

Lisa Holloway

Lisa joined PharmaVentures as Senior Marketing Manager, bringing over 25 years’ experience across a range of marketing management roles.

Lisa began her career in the life science and healthcare industry at PharmaVentures. Her marketing experience expands across industries including as food, automotive, nuclear, oil and gas, motorsport and defence for companies involved in performance engineering, aerodynamics and thermodynamics.

Lisa holds qualifications from the Chartered Institute of Marketing (CIM) and a certificate in Legal Practice from OCFE/Coventry University.

Corporate-Advisory
Vice President

Kate Moore

Kate has been an advisor or key player on the following PharmaVentures M&A mandates:

• Sanofi divestment of Slovak manufacturing site to Wood&Co (2013),
• Merck divestment of R&D facility to BioCity (2012),
• Canadian Biotech out-licensing to mid-size European Pharma Co. (2011),
• Sanofi divestment of 2 R&D sites to Covance (2010),
• UCB sale of 3 manufacturing sites to Aesica (2010) and
• Dr Reddy’s in-licensing of consumer health brands from Vitabiotics (2010).

Kate has more than 15 years of experience in the biotechnology industry and a successful track record in negotiating in and out licensing deals, conducting market evaluations and technical and commercial due diligence.

Kate holds an undergraduate degree from Oxford University and a PhD in Molecular Biology from University College London. Prior to joining PharmaVentures, her previous positions include marketing and research at BD Biosciences, BioCarta and Prolifix. More recently, Kate was the Director of Business Development at TopoTarget.

Corporate-Advisory
Vice President

Ralph Hughes

Ralph is a Vice President at PharmaVentures with experience in Pricing and Market Access and Commercial and Business Development.

He has held various roles in the pharmaceutical industry. For Mundipharma, he developed the commercial and market access strategy for development and launch assets. At Pfizer, he developed market access and pricing strategies across the globe and across multiple disease areas for both early, late stage and in-market assets. He has delivered marketing campaigns, global forecasts, HTAs, pricing strategies, real world data studies, and economic models; through this, Ralph has a deep understanding of what it takes to commercialise an asset in the pharmaceutical industry.

He holds a MSc in Public Health and Health Economics from the London School of Hygiene and Tropical Medicine and a BSc in Biomedical Sciences from Newcastle University.

Corporate-Advisory
Vice President

Jansen Jacob

Jansen is a healthcare transactions professional with nearly 30 years in the life science sector with expertise in M&A, licensing, strategy and commercial DD. Jansen has considerable experience in the pharma services sector having advised on the strategic direction of over 40 different R&D and manufacturing operations. Jansen has taken key roles in many M&A mandates for clients such as Novartis, Sanofi, Merck and UCB.

Fluent in Malayalam and Hindi, Jansen holds a PhD in Biochemistry from the University of Sussex and an MBA from Oxford Brookes University.

Corporate-Advisory
Senior Director

Asif Shahinsha

Asif is a Senior Director at PharmaVentures.

Asif is an M&A and corporate finance professional with 20 years of diverse experience. He has advised clients operating in pharma, medical devices, digital health and healthcare services in the US, UK, EU and India. He has successfully led M&A, capital raising and IP monetisation assignments.

Over the years, he has worked at Citi (New York), Wedge Alternatives (London) and other boutiques building successful relationships with founders, VC/PE investors and corporate M&A teams. ​Asif graduated with a BSc in Physics from Bharathidasan University and an MSc from London School of Economics and Political Science.​

Corporate-Advisory
Director

Kyriakos Tzafestas

Kyriakos joined PharmaVentures as an Associate.

Prior to joining PharmaVentures, Kyriakos was a life sciences consultant working with biotech companies and early-stage technologies on projects encompassing market analysis, competitive intelligence, opportunity assessment, commercialisation roadmaps, patent landscaping, valuations, and business development for research collaborations and licensing opportunities. Kyriakos has also served as the Industry Programme Manager for the Royal Society, overseeing their research translation programme and advising public policy on Research & Innovation.

Before commencing his professional career, Kyriakos completed a Master of Biotechnology (Distinction) at the University of Glasgow and obtained a PhD in Molecular Biology from the University of York.

Corporate-Advisory
Business Development Executive

Dong Hyun (Danny) Chung

Dong Hyun is a Business Development Executive at PharmaVentures.

Prior to joining PharmaVentures, Dong Hyun worked at a specialty biotech company as a business development associate, where he supported business development efforts across a range of therapeutic areas including ophthalmology, and CNS disorders.

Dong Hyun holds a BSc in Biomedical Science from King’s College London, and an MSc in Drug Discovery and Pharma Management from University College London.

Corporate-Advisory
Snr Associate

Peter Kalpakov

Before joining PharmaVentures, Peter had a background in investment banking, corporate development and private equity primarily in the Healthcare and Biopharma sector. He has worked for leading firms, such Investec, Stifel/Torreya, Deloitte and Eurohold PE, Xerox. He has worked on a number of strategic advisory, licensing and M&A mandates, both as an investor and as advisor, assisting his clients find the optimal solutions to their challenges across UK, Europe, US and APAC region. He focuses on Bioproduction, Pharma Services (inc. CROs, CDMOs), LS Tools, Medtech and Cell and Gene Therapy.

Peter earned an MPharm in Pharmacy from University of Strathclyde and an MSc in Corporate Finance and Banking from SDA Bocconi. He is fluent in English, Italian, Bulgarian and Russian.

Corporate-Advisory
Associate

Fabio Tommasini

Prior to joining PharmaVentures, Fabio worked as an Associate Consultant at Prescient Healthcare Group, focussing on competitive intelligence in oncology and haematology.

Fabio has been awarded a PhD in Tissue Engineering at University College London. During his studies, Fabio led the London Chapter of a Global Accelerator programme for seed-stage companies focussed on life sciences, digital health, clean-tech and advanced engineering, at Innovation Forum and joined Waimangu Ventures as an intern, backing the venture capital and consulting functions of the firm.

Fabio also holds a MSc in Molecular Medicine at Imperial College London and a BSc in Biotechnology from the University of Verona.

Corporate-Advisory
Associate

Enrique Bendito-Moll

At PharmaVentures, Enrique has supported European and Asian biotechs, pharmaceutical companies and VC funds across a range of transactions and strategy mandates. He has experience in M&A, licensing, valuations, and indication prioritisation projects amongst others.

Enrique joined PharmaVentures having spent 5 years at GlaxoSmithKline (Stevenage, UK), where he conducted his PhD research in the field of Protein Degradation.

Enrique is fluent in Spanish, Catalan and English. He holds a PhD in Chemical Biology (GlaxoSmithKline/University of Strathclyde, UK) and a master’s degree in Pharmacy (Universitat de Barcelona, Spain).

Corporate-Advisory
Senior Analyst

Thomas Hickman

Thomas is a Senior Analyst at PharmaVentures.

Prior to joining PharmaVentures, Thomas worked at a global health intelligence and analytics agency where he developed predictive models for forecasting global COVID-19 vaccine demand and supply as well as epidemiological trends.

He also has extensive Research experience in Molecular Biology and Biochemical Engineering having completed a Post-doctoral Research Fellowship at University College London (UCL) partnered with the Ministry of Defence, a PhD in Biochemical Engineering (UCL), a Masters in Synthetic Biology (UCL) and a BSc in Biological Sciences (University of Exeter).

Corporate-Advisory
Senior Analyst

Rebeca Garcia

At PharmaVentures, Rebeca has supported biopharma companies and medical device manufacturers across M&A, fundraising, licensing and market access mandates.

Before joining the firm, Rebeca was part of a boutique consultancy providing strategic guidance to life sciences firms. Prior to this, she advised early-stage technologies at the commercialisation teams of Imperial College London and the Polsky Center Chicago, and also worked in the corporate commercial division at Samsung.

Rebeca completed her academic studies at the University of CEU San Pablo and at the University of Chicago. She also speaks Spanish, English, Italian and French.

Corporate-Advisory
Associate

Andreas Katsiamides

Andreas is an Associate at PharmaVentures.

He has experience in Molecular Biology and Medical Diagnostics. Prior to joining PharmaVentures, Andreas worked in competitive intelligence consulting firms, supporting with commercial/competitor due diligence and opportunity and threat assessments across a range of therapy areas including oncology, personalised healthcare, and infectious and rare diseases.

Andreas holds a BSc in Molecular Genetics and Pharmacology and a PhD in Molecular Neurobiology, both from the University of King’s College London (UK).

Corporate-Advisory
Analyst

Wenshi He

Wenshi joined PharmaVentures with a broad range of experience in Drug Regulation, Market Access, Oncology, and Multi-omics research. She was part of the Regulatory Operations team at Pfizer’s China R&D Center in Shanghai. Prior to this, she gained market access experience from her dissertation research with a multinational management consulting firm. She is fluent in English, Mandarin, and Cantonese. 

Wenshi holds an MSc in Drug Development Science from King’s College London and a PhD in Analytical Bioscience from University of Nottingham.

Corporate-Advisory
Analyst

Sarah Elsayed

Sarah joined PharmaVentures as an Analyst with over 8 years of versatile experience in pharmaceutical market intelligence, regulatory affairs, and marketing.

Prior to joining PharmaVentures, Sarah worked as a Pharma and Healthcare analyst authoring syndicated reports that provided in-depth strategic analyses of products, opportunity assessment, and sales forecasting across major markets.

Sarah also worked at GlaxoSmithKline over a 5-year period across different functions in regulatory and commercial departments, where she supported product life cycle management, market access, and respiratory key account management.

Sarah holds a Master of Business Administration (MBA) from Lancaster University, and a BSc in Pharmaceutical Sciences from Ain Shams University.

Corporate-Advisory
Expert Advisor

With over 35 years’ experience in the biologics industry Steve’s career has covered the manufacturing, process development, business development and general management of vaccine (human and animal), recombinant proteins, monoclonal antibodies and cell and gene therapy product supply.  Steve has worked in both the CDMO and multi-product organisations and has extensive experience of microbial, yeast and mammalian cell culture systems ranging from less than 500mL to 12,000L scale using single use disposable and purpose designed and built stainless steel equipment.

A microbiologist by education Steve has lived and worked in the Netherlands.  He has led technology transfer projects into, out of and within the UK, has worked as a process expert on facility design and build within and without of the UK and has been process/facility lead on several M&A assignments.

Corporate-Advisory
Expert Advisor

Nigel Borshell

Nigel joined the team back in 2008 and brings to PharmaVentures’ clients specialist expertise in valuation methodologies, deal structuring modelling and pricing, and has extensive experience in major global pharmaceutical corporation site divestments in the USA and across Europe.

With a strong background in senior international commercial management roles in both diagnostics and biotechnology firms, Nigel brings insight into a breadth of life science industry sectors gained at drug testing specialists Syva Company, at Hoechst, US diagnostics leader Dade Behring, and as European Business Development Director for the California-based molecular biology company Cepheid.

With over 35 years experience in Life Sciences Nigel is the author of numerous Pharmaceutical/Biotech Industry reports, papers and articles, including most recently:-

The Royalty Rate Report 2012: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector; Cartwright & Borshell; ISBN: 978-0-9568270-2-9 Print

Approaches to Valuation of Pharmaceutical Licensing Deals; Ahmed & Borshell; Published by PharmaDeals 2012, ISBN 978-0-9568270-6-7 Print

Valuation benefits of structure-enabled drug discovery: Borshell & Congreve; Nature Reviews Drug Discovery, March 2011, Volume 10.

Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumb; Borshell & Dawkes, Journal of Commercial Biotechnology,Vol 16, No 1 (2010).

Corporate-Advisory
Regional Advisor

Paul MacLeman

Paul joins PharmaVentures as a member of the Advisory Board based in Australia. Bringing over 25 years’ board and executive experience across the life sciences, agricultural and not-for-profit sectors. His experience ranges from strategy formulation to capital raising, business development, technology commercialisation and sales & marketing.

Paul’s work portfolio spans working as a Vice President in Animal Health at Agenix Ltd, Managing Director at Hatchtech Pty Ltd and Chief Executive Officer at Genetic Technologies Ltd. Paul is currently Chair of AdAlta Limited, Livac Pty Limited, and is Non-Executive Director of Sypharma Pty Limited. He has also launched a variety of products in Australia, the US and Asia, founded life sciences start-ups in the biologics area and worked in investment banking.

Paul graduated with a Bachelor of Veterinary Science from the University of Sydney. In addition, Paul also completed a postgraduate certificate in engineering at Swinburne University of Technology and Master of Business Administration degree at Macquarie University.

Corporate-Advisory
Regional Advisor

Sue MacLeman 

BPharm, LLM, MMkt, FAICD, FATSE, FACPP

Sue joined PharmaVentures as a member of the Advisory Board based in Australia.

Sue has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has served as CEO and Board member of several ASX, AIM  and NASDAQ listed companies in the healthtech sector. She is currently Non Executive Director at Rhythm Biosciences Ltd, Planet Innovation Holdings, Australian Academy of Technology and Engineering (ATSE)  and Omico. Sue is also appointed to several industry, academic and government advisory boards. Her broad commercial and technical experience is underpinned by a Bachelor of Pharmacy from the University of Queensland, a Master of Laws from Deakin University and a Master of Marketing from Melbourne Business School. She ­is also a Fellow of ATSE and Fellow/Graduate of Australian Institute of Company Directors (AICD).

Corporate-Advisory
Regional Advisor

Aki von Roy

Aki von Roy has over 30 years’ experience in big pharma and 16 years in biotech and has been involved in over 18 start-up or merger ventures as director or investor. These include Founder CEO of Proacta and CoDa Therapeutics and founding director of Corra Life Sciences (USA), Biomatters (NZ) and White Biotech (AUS).

Aki is the former European president of Bristol-Myers Squibb, where he was responsible for US$ 2.2 billion in sales, more than 7,500 employees and some 40 subsidiaries. In 1997, he retired from BMS to establish RvR Associates, a private investment firm specialising in health and related matters.

Former chairman of both private and publicly traded companies such as Genesis R&D, Phylogica, Vital Foods and Phytomedics Aki is now a Venture Partner at BioPacificVentures and an advisor to Direct Capital. He was previously a partner of Inventages (US$ 1.5 billion life science fund).

Corporate-Advisory
Senior Advisor

Frank Dollard

Frank has a 40-year track-record of success and innovation in the Pharmaceutical Industry working for Glaxo, BMS and Pliva. His main experiences cover Manufacturing, Quality Management, Commercial, Supply-Chain and Procurement (Strategic Sourcing) within the ethical & generic pharmaceutical and devices industry. He has formed and led teams in Europe/USA/Latin America and the Pacific Rim. Frank is a chemistry graduate from the University of Liverpool. Since joining PharmaVentures, Frank has opined on multiple divestment projects, including the recent sale of Novartis’ manufacturing plants to Siegfried.

Corporate-Advisory
Regional Advisor

Christopher Berry

Dr Christopher Berry previously worked on R&D Transactions within Sanofi R&D, where he was responsible for building research collaborations (ranging from material transfer agreements through to multi-scaffold drug discovery deals) in the areas of anti-infectives, biologics, and regenerative medicine, as well as for the Asia-Pacific Therapeutic Unit. In addition he was also responsible for opportunity scouting in the UK across all therapeutic areas. He had over 14 years experience in research alliance building and alliance management. He was previously Head of Thrombosis and Haematology in Synthélabo Recherche (one of Sanofi’s predecessor companies), which was the culmination of 16 years in discovery research which began in 1984 when he joined Synthélabo’s Pain and Inflammation group, after a brief flirtation with academic research. He is a member of the panel of KHIDI (Korean Health Industry Development Institute) Key Opinion Leaders in their business development support section. He obtained his PhD in Pharmacology at King’s College, London in 1981, and an MBA at the Open Business School in 2003.

Corporate-Advisory
Associate

Pierre Duda

Pierre joined PharmaVentures as a Business Analyst bringing experience from life sciences asset valuations and pharmaceutical marketing.

Prior to joining the company, Pierre was working as a Financial/Business Analyst in a consulting firm in Münich (Germany) and worked on market models, revenue forecasts, risk analysis, development plans, and cost estimates, incorporated in financial and licensing models. Pierre also had the opportunity to manage out-licensing projects for in-development stage assets.

Also, Pierre had a career in marketing holding the position of Junior Product Manager in France for two companies, Imaxio (now Osivax) and Abbott Diabetes Care.

Pierre studied pharmacy at Lyon University (France) and holds a Masters’s degree from Grenoble Business School (France) in Biopharmaceutical Management. Pierre is fluent in French, English, and Polish and can speak German.

Corporate-Advisory
Associate

Since joining PharmaVentures, Fotis been involved in multiple buy- and sell-side mandates as well as commercial strategy projects where he  closely worked with both Asian and Western companies.

Prior to joining the company, Fotis worked as a Competitive Intelligence Analyst, closely monitoring the competitive landscape of several therapeutic areas such as CNS and Autoimmune disorders. Fotis has also worked for a large financial group where he provided pharmaceutical market size forecasts for several countries, along with analysing wider industry trends.

He holds a BSc in Chemistry from Aristotle University in Thessaloniki and an MSc in Drug Development Science from King’s College London. He is fluent in Greek and English and can also speak Spanish.

Corporate-Advisory
Associate

JungHyun is an Associate with experience in representing early stage biotechs in their out-licensing efforts and providing strategic consulting, as well as supporting internal BD activities.

Prior to PharmaVentures, she worked at a Korean pharmaceutical company as a project and alliance manager for CDMO business, which ranged from early clinical R&D to commercial production. She holds a BSc and MSc in Biological Sciences from Korea Advanced Institute of Science and Technology (KAIST). She is fluent in English and Korean and is currently based in South Korea.

Corporate-Advisory
Senior Analyst

Ross Jenkins

Ross joined PharmaVentures as a Business Analyst, with previous experience in diagnostic start-ups and commercialisation.

Prior to joining PharmaVentures, Ross worked at a multiplex immune-diagnostic start-up in New Zealand focused on both human and animal health. During this time he was involved across all areas of the business from communications, manufacturing, quality/regulatory affairs, and market analysis. 

Ross holds a BSC(Hons) in Biotechnology and, a PGDip and Masters in Bioscience Enterprise from the University of Auckland.

Corporate-Advisory
ASSOCIATE

Akanksha Manglani

Akanksha joined PharmaVentures as an Associate. She worked for BDO as Senior M&A Associate, Corporate Finance and Investment Banking. She worked with a wide range of companies to create deliverables, provide strategic advice, and participate in Negotiations and Deal Closures. At Grant Thornton, she introduced new research techniques to help create a research arm dedicated to Private Equity Funds. As a consultant, she has analysed global pharmaceutical industry trends providing a variety of solutions to overcome major challenges in the industry in partnership with Deloitte Sydney.

Akanksha holds a Master of Business Administration (MBA) from the University of Bath.

Corporate-Advisory
Director

Gian Andrea Dell Antonio

Gian has a background in healthcare investment banking. He worked in Shanghai and London for an M&A boutique where he originated and advised several healthcare cross border transactions across APAC region, US and Europe. He has developed significant experience in the valuation of life science M&A and licensing transactions, financial statement analysis and company/asset due diligence. He also built strong relationships with corporates, financial sponsors and other investment bank boutiques to successfully improve deal flow for the firm.

Gian holds a BSc in Economics & Finance from Bocconi University and MSc double degree in Finance from Xi’An Jiaotong-Liverpool University. He is fluent in English, Italian and learning Mandarin.

Corporate-Advisory
Vice President

Jessie (Sangmin) You

Jessie has experience in drug development across different product life cycles from pre-clinical to post-marketing.

Prior to joining PharmaVentures, Jessie worked at Pfizer, Celgene and ILIAS Biologics across different functions in medical affairs and regulatory/clinical project management, supporting product launch and reimbursement, managing post-marketing surveillance studies, investigator-initiated trials, research collaborations, competitive intelligence and IND filing.

Jessie holds a BSc in Chemistry, a MSc in Pharmaceutical Sciences, and a PharmD, all from the University of Rhode Island (USA).

Corporate-Advisory
ANALYST

SeungHwan Song

SeungHwan joined PharmaVentures as an Analyst with a broad range of experience covering the biopharmaceutical industry, healthcare policy and IT healthcare.

Prior to joining PharmaVentures, SeungHwan worked at Samsung Bioepis, one of the biggest biosimilar companies, as a manager of the corporate planning team where he worked on market analysis, business development and developing new business area. He also participated in the IT strategy group, aiming to develop the technology roadmap and lead the digital transformation. He has experience in the public institute in South Korea, leading projects regarding healthcare policy and regulation.

SeungHwan holds a BSc in Health Science from Korea University, an M.Eng in Technology Management/Corporate Strategy from Seoul National University.